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Summary
Background Respiratory syncytial virus (RSV) infection is an important cause of pneumonia mortality in young 
children. However, clinical data for fatal RSV infection are scarce. We aimed to identify clinical and socioeconomic 
characteristics of children aged younger than 5 years with RSV-related mortality using individual patient data.
Methods In this retrospective case series, we developed an online questionnaire to obtain individual patient data for 
clinical and socioeconomic characteristics of children aged younger than 5 years who died with community-acquired 
RSV infection between Jan 1, 1995, and Oct 31, 2015, through leading research groups for child pneumonia identified 
through a comprehensive literature search and existing research networks. For the literature search, we searched 
PubMed for articles published up to Feb 3, 2015, using the key terms “RSV”, “respiratory syncytial virus”, or 
“respiratory syncytial viral” combined with “mortality”, “fatality”, “death”, “died”, “deaths”, or “CFR” for articles 
published in English. We invited researchers and clinicians identified to participate between Nov 1, 2014, and 
Oct 31, 2015. We calculated descriptive statistics for all variables. 
Findings We studied 358 children with RSV-related in-hospital death from 23 countries across the world, with data 
contributed from 31 research groups. 117 (33%) children were from low-income or lower middle-income countries, 
77 (22%) were from upper middle-income countries, and 164 (46%) were from high-income countries. 190 (53%) 
were male. Data for comorbidities were missing for some children in low-income and middle-income countries. 
Available data showed that comorbidities were present in at least 33 (28%) children from low-income or lower middle-
income countries, 36 (47%) from upper middle-income countries, and 114 (70%) from high-income countries. 
Median age for RSV-related deaths was 5·0 months (IQR 2·3–11·0) in low-income or lower middle-income countries, 
4·0 years (2·0–10·0) in upper middle-income countries, and 7·0 years (3·6–16·8) in high-income countries.
Interpretation This study is the first large case series of children who died with community-acquired RSV infection. 
A substantial proportion of children with RSV-related death had comorbidities. Our results show that perinatal 
immunisation strategies for children aged younger than 6 months could have a substantial impact on RSV-related 
child mortality in low-income and middle-income countries.
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Introduction
Respiratory syncytial virus (RSV) infection is the primary 
pathogen identified in children with acute lower respiratory 
tract infection during the first year of life.1–4 RSV-related 
acute lower respiratory tract infection is an important 
cause of death in young children (aged younger than 
5 years); approximately 48 000–74 500 children in this age 
group died in hospital with the condition in 2015.5 About 
99% of RSV-related childhood mortality occurs in 
developing countries.5 Although RSV-related mortality in 
children poses an important global health problem, clinical 
data for global RSV-related mortality are scarce. Data 
suggest that most RSV-related childhood mortality occurs 
during the first year of life.6–8 Although the case fatality rate 
is highest in children with underlying conditions, such as 
congenital heart disease, chronic lung disease, Down’s 
syndrome, or premature birth,7–13 most cases of life-
threatening RSV infection occur among previously healthy 
children.14–16 This finding suggests that in settings without 
intensive care facilities, otherwise healthy children could 
also be at risk of dying from RSV infection. A study from 
Argentina16 reported that poor access to intensive care was 
associated with RSV-related death.
RSV-related mortality in young children has primarily 
been described sporadically in studies10,11,14,17 from intensive 
care units in high-income or middle-income countries. 
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To date, the largest case series11 of 35 RSV-related deaths 
was reported from an intensive care unit in the UK, with 
numbers smaller than 35 having been reported in other 
studies.2,16,18,19 In 2015, the WHO’s Product Development 
for Vaccines Advisory Committee identified RSV as “a 
pathogen for which there is major vaccine pipeline 
activity”, with a vaccine likely to be available in the next 
5–10 years.20
Two broad approaches to RSV immunisation are being 
considered in young children: maternal immunisation 
for children aged younger than 6 months and paediatric 
vaccines for children aged older than 6 months. A good 
understanding of the age distribution of RSV-related 
deaths is likely to assist in development of an evidence 
base to inform vaccine policy, particularly in low-income 
and middle-income settings.21
Previous reports of RSV-related mortality in young 
children described studies done in one centre, region, or 
country. None of them were large enough to draw robust 
conclusions on the clinical and socioeconomic profile 
of children who die with community-acquired RSV 
infection globally. To gain insight into the clinical 
characteristics of RSV-related mortality in young 
children, we initiated the RSV Global Online Mortality 
Database (RSV GOLD) study with the aim to gather 
available retrospective data for fatal community-acquired 
RSV infections across the world.
Methods
Study design and patients
RSV GOLD is a global study that retrospectively analysed 
individual data for children aged 0–59 months who died 
with community-acquired RSV infection between Jan 1, 
1995, and Oct 31, 2015. We identified research groups 
through a comprehensive literature search on PubMed 
(for articles published up to Feb 3, 2015) using the key 
terms “RSV”, “respiratory syncytial virus”, or “respiratory 
syncytial viral” combined with “mortality”, “fatality”, 
“death”, “died”, “deaths”, or “CFR”. We limited the search 
to papers written in English with the abstract and full text 
available. We invited authors of scientific, peer-reviewed 
papers reporting RSV-related mortality in children to 
collaborate. Additionally, we obtained unpublished 
individual patient data from researchers and clinicians 
who we identified via research networks. We invited 
researchers and clinicians to participate in this study 
between Nov 1, 2014, and Oct 31, 2015. We included data 
for children with laboratory-confirmed RSV infection 
and excluded cases of nosocomial or post-stem cell 
transplantation RSV infection. Since this study only used 
anonymised secondary data, the institutional research 
board of the University Medical Centre Utrecht waived 
the requirement for parental informed consent.
Procedures
We collected data using an online questionnaire designed 
by a group of investigators (NMS, LJB, HN, FPP, BDG, 
and DEG). The questionnaire aimed to collect information 
about clinical and socioeconomic charac teristics of 
children with RSV-related mortality. Characteristics of 
interest were based on risk factors for RSV-related and 
pneumonia-related mortality as described in the literature 
and on expert opinion (appendix).
We carefully validated patient information by direct 
communication with participating researchers for data 
entry errors, missing variables, and conflicting data. We 
deemed age at death within 0–59 months, laboratory-
confirmed RSV diagnosis, and community-acquired RSV 
infection minimum essential data for inclusion. After 
assessment of data quality, we excluded children if 
Research in context
Evidence before this study
Respiratory syncytial virus (RSV) infection is a leading cause of 
global acute lower respiratory tract infection in young children. 
It was associated with 48 000–74 500 in-hospital deaths in 
children aged younger than 5 years in 2015, with 99% of these 
deaths occurring in developing countries. However, individual 
patient data for RSV-related deaths are scarce. We searched 
PubMed for articles published in English up to July 7, 2017, using 
search terms related to RSV infection, pneumonia, and childhood 
mortality. We found case series of RSV-related child deaths that 
reported 35 cases or fewer.
Added value of this study
We did, to our knowledge, the first case series of children who 
died with RSV infection to define clinical and socioeconomic 
characteristics of RSV-related mortality. We searched the 
literature using PubMed for “RSV”, “respiratory syncytial virus”, 
or “respiratory syncytial viral” combined with “mortality”, 
“fatality”, “death”, “died”, “deaths”, or “CFR” for articles 
published up to Feb 3, 2015, in English, to identify research 
groups with relevant cases and obtained additional cases 
through existing research networks. We report on 
358 in-hospital deaths with laboratory-confirmed RSV infection 
from 23 countries across the world. A substantial proportion of 
in-hospital RSV-related deaths occurred in children with 
pre-existing comorbidities. Most children in low-income and 
middle-income countries were aged younger than 6 months at 
the time of death.
Implications of all the available evidence
This study is the first case series of children who died with RSV 
infection in hospital, giving insight into the clinical and 
socioeconomic background of children with RSV-related death. 
Young age at death supports the concept that maternal 
vaccination against RSV infection could be an eﬀective strategy 
to prevent RSV-related childhood mortality.
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nosocomial infection could not be ruled out on the basis 
of available clinical information or if death occurred 
before 1995. We sent additional questions about 
admission to paediatric intensive care units and 
availability of mechanical ventilation to the participating 
researcher if this information could not be extracted 
from the shared data.
We defined the following patient populations: children 
with comorbidities, healthy term children, and preterm 
children without other comorbidities (healthy preterm 
children). Children with comorbidities had at least 
one underlying disease, such as congenital heart disease, 
a genetic or chromosomal disorder, HIV infection, or 
active tuberculosis. Healthy term children were born 
without comorbidities at 37 weeks’ gestational age or 
later and healthy preterm children were born without 
comorbidities at earlier than 37 weeks’ gestational age. 
When data for comorbidities or prematurity were not 
recorded, we assumed that the children were healthy 
term. We categorised countries as high income, upper 
middle income, lower middle income, or low income on 
the basis of the World Bank classifications for 2016.22 
We considered Hong Kong and Taiwan high-income 
countries in line with the World Bank classification. The 
composite variable neurological disease consisted of 
neurodevelopmental, neuromuscular, and other neuro-
logical disease, such as epilepsy or encephalopathy.
Statistical analysis
We calculated descriptive statistics for all variables. We 
provide frequencies and proportions for categorical 
variables. We report the summary results for continuous 
variables as medians with IQRs. We analysed data by 
World Bank income regions. Additionally, we analysed 
data separately for children with comorbidities, healthy 
term children, and healthy preterm children. Using WHO 
child growth standards,23 we calculated Z scores for weight 
for age, height for age, and weight for height. We did not 
correct weight for age for gestational age. 
To rule out bias, we did sensitivity analyses excluding 
cases with missing data for prematurity or comorbidities 
to test our assumption that children with missing data 
were healthy term. Similarly, we analysed to what extent 
our results were sensitive to the contribution of a large 
number of cases from Argentina and Kenya by doing 
analysis without these countries. We tested meaningful 
subgroup diﬀerences for significance with Kruskal-
Wallis or χ² statistical tests. We did further paired testing 
between subgroups using Mann-Whitney U or χ² tests 
with Bonferroni correction for multiple testing. We did 
not test subgroup diﬀerences of results presented in 
the appendix for significance. We did all statistical 
analyses with SPSS statistical software (version 22.0).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
NMS and LJB had full access to all the data in the study 
and the corresponding author had final responsibility for 
the decision to submit for publication.
Results
The literature search resulted in 1154 publications 
(figure 1). From these publications, we identified 
85 research groups, which we complemented with 
research groups identified through existing research 
networks, particularly through the RSV Global 
Figure 1: Study selection
RSV=respiratory syncytial virus.
1154 potentially eligible 
studies identified by 
database search 
175 studies identified for 
full-text screening 
979 excluded after title and abstract 
screening
82 excluded after full-text screening
4 full text not available
11 review or modelling study
11 done before 1995
38 no RSV mortality
3 aged 5 years or older
8 post-transplant RSV
7 nosocomial RSV
93 studies identified 
for research group 
selection
8 excluded as published by same 
research group
85 research groups 
identified
67 research groups identified via 
research networks 19 excluded as same research groups
133 research groups 
contacted
65 research groups 
responded
31 research groups 
contributed data
for 451 children
68 excluded as no response 
45 literature search
23 networks
34 excluded
21 no RSV mortality data available
3 literature search
18 networks
13 data not contributed
5 literature search
6 networks
2 lost contact
358 children included
93 excluded after assessment of data 
quality
75 nosocomial RSV
6 duplicate entry 
2 no laboratory-confirmed RSV 
diagnosis
2 from 1994
1 aged 5 years or older
7 posthospital discharge deaths 
of unknown cause
Articles
e987 www.thelancet.com/lancetgh   Vol 5   October 2017
ICREA, Catalan Institution for 
Research and Advanced Studies, 
Barcelona, Spain, Department 
of Pediatrics, Hospital Sant Joan 
de Déu, Barcelona, Spain, Centro 
de Investigação em Saúde de 
Manhiça, Maputo, 
Mozambique, and Faculty of 
Medicine, Universidad Europea 
de Madrid, Madrid, Spain 
(Q Bassat PhD); Department of 
Intensive Care, Royal Children’s 
Hospital, Melbourne, VIC, 
Australia, Department of 
Paediatrics, University of 
Melbourne, Melbourne, VIC, 
Australia, and Murdoch 
Children’s Research Institute, 
Parkville, VIC, Australia 
(W Butt MD); Department of 
Pediatric Infectious Disease, 
MacKay Children’s Hospital, 
Taipei, Taiwan (H Chi MD); 
Department of Virology, 
National Institute of Health, 
Islamabad, Pakistan 
(U B Aamir PhD); Department of 
Paediatrics and Child Health, 
Aga Khan University, Karachi, 
Pakistan (A Ali MBBS); Public 
Health Institute, Ñuñoa, 
Santiago, Chile (R A Fasce BSc); 
Hospital Dr. Ernesto Torres 
Galdames, Iquique, Chile 
(O Lopez MD); Vienna Vaccine 
Safety Initiative, Berlin, 
Germany, and University of 
Nottingham School of 
Medicine, Nottingham, UK 
(B A Rath PhD); Fundacion 
Infant, Buenos Aires, Argentina 
(F P Polack MD); Department of 
Microbiology, Division of 
Pediatric Infectious Diseases, 
McGill University Health Centre, 
Montreal, QC, Canada 
(J Papenburg MD); Department 
of Paediatric Infectious 
Diseases, University Hospital for 
Infectious Diseases, Zagreb, 
Croatia (S Roglić MD); 
Department of Pediatrics, 
Nantan General Hospital, Ueno, 
Yagichoyagi, Nantan-shi, Kyoto, 
Japan (H Ito MD); School of 
Health and Related Research, 
University of Sheffield, 
Sheffield, UK (E A Goka PhD); 
Julius Global Health, Julius 
Center for Health Sciences and 
Primary Care, University Medical 
Center Utrecht, Utrecht, 
Netherlands, and Julius Clinical 
Science, Zeist, Netherlands 
(D E Grobbee PhD); and Centre 
for Global Health Research, 
Usher Institute of Population 
Health Sciences and Informatics, 
University of Edinburgh, 
Edinburgh, UK (H Nair PhD) 
Epidemiology Network.5 We obtained data for 
451 children with RSV-related mortality from the 
31 research groups that shared data. We obtained both 
published and unpublished cases. Using original 
publications to contact research groups, we estimated 
that we could have missed a maximum of 140 cases from 
the published literature as most researchers who did not 
respond to our invitation to participate had reported 
solitary cases of RSV-related mortality: in 28 publications, 
the number of potential RSV-related deaths was 
mentioned and in 15 (54%) of those, one or two RSV-
related deaths were described. Many non-responders 
were research groups from high-income countries 
(41 [60%] of 68) and had published their results between 
2010 and 2015 (21 [47%] of 45). Publications used to 
identify research groups that contributed data are shown 
in the appendix. After initial assessment of the 
451 children, we excluded 93 (21%). Most exclusions 
were associated with nosocomial RSV infection. We 
excluded six (1%) duplicate entries. We included 
358 (79%) children with RSV-associated mortality 
originating from 23 diﬀerent countries across the world 
(figure 2, appendix). RSV diagnosis was established 
most often by immunofluorescence or PCR (appendix). 
PCR was mostly used in children who died after 2005. 
Clear seasonality with an annual peak was reported in 
18 (78%) of the 23 countries.
117 (33%) children were from low-income or lower 
middle-income countries, 77 (22%) were from upper 
middle-income countries, and 164 (46%) were from 
high-income countries (table). 190 (53%) children were 
male; we observed no sex diﬀerences between countries of 
diﬀerent incomes. Children from high-income countries 
had a higher median age at death than did those in 
low-income or lower middle-income countries and 
children from high-income countries had stayed in hospital 
for a longer period and were more often admitted to a 
paediatric intensive care unit than those from upper 
middle-income countries or low-income or lower 
middle-income countries. Median time between onset of 
symptoms and death was longer in children from high-
income countries (21·0 days [IQR 12·0–37·0]) than in 
those from low-income or lower middle-income countries 
(9·5 days [7·0–16·8]) or upper middle-income countries 
(10·0 days [8·0–14·0]; appendix).
We analysed the prevalence of comorbidities in our 
study (table) and distinguished clinical characteristics of 
children with and without comorbidities (appendix). 
Data for comorbidities were missing for some children. 
Available data showed that comorbidities were present in 
at least 183 (51%) children. Congenital heart disease was 
the most frequent comorbid condition identified. The 
proportion of children with comorbidities was similar 
during sensitivity analyses when children with missing 
data (for comorbidities and gestational age) were 
excluded, except that the proportion with comorbidities 
in low-income or lower middle-income countries was 
more than doubled (appendix). Specific information 
about the presence of comorbidities and prematurity was 
available in 243 (68%) children. The proportion of 
missing information about comorbidities and 
prematurity was similar for children aged younger than 
6 months at the time of death (54 [30%] of 178) and older 
children (61 [34%] of 180).
Figure 2: Locations of the respiratory syncytial virus-related deaths in young children included in the analysis
Numbers of deaths are given for each country included.
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We analysed how the presence of comorbidities 
aﬀected age at death (figure 3). Most healthy term and 
healthy preterm children were aged younger than 
6 months at the time of RSV-related death (appendix). 
The proportion of children aged younger than 6 months 
at the time of death was even larger when only children 
with complete data for comorbidity and gestational age 
status were included than when all children were 
included (appendix). Age at death of children with 
comorbidities from high-income countries was higher 
than that of those from low-income or middle-income 
countries.
We analysed the proportion of children with low 
weight for age. More than half of all children had a 
weight for age of less than –2 SDs (table). In high-
income countries, this finding was mainly explained by 
a large proportion of preterm children and children 
with comorbidities. Only eight (28%) of 29 healthy 
term children in high-income countries had low weight 
for age compared with eight (89%) of nine healthy 
preterm children and 33 (54%) of 61 children with 
comorbidities (appendix). By contrast, in the other two 
income regions, we found a high proportion (≥48%) of 
low weight for age in all three children groups, 
including healthy term infants.
Data for co-infection were scarce. Microbiological 
data other than RSV diagnosis were sparsely available. 
We identified co-pathogens in 70 children, with 
22 (31%) who tested positive for two or more pathogens 
besides RSV (data not shown). Positive blood cultures 
were reported in four (6%) children (two [3%] with 
Pseudomonas aeruginosa, one [1%] with Klebsiella spp, 
and one [1%] with Staphylococcus aureus).
Data from Argentina (78 [22%]) and Kenya (43 [12%]) 
contributed to about one third of all RSV-related deaths 
(121 [34%]). We did a sensitivity analysis excluding these 
data. The results from these analyses showed a higher 
age at death for children from high-income countries 
(10·0 months [4·0–24·0]) than from upper middle-
income (4·0 months [2·0–10·0]) or low-income or lower 
middle-income (4·0 months [2·2–7·0]) countries, which 
was the same trend as for the main analysis. Other 
clinical characteristics, including sex and the proportion 
of prematurity or comorbidities, were also unchanged 
from the main analysis (data not shown).
Discussion
Severe RSV infection is one of the major causes of 
global mortality in young children, with 99% of deaths 
occurring in developing countries in 2015.5 RSV GOLD 
Low-income or lower 
middle-income 
countries (n=117)
p value* Upper middle-income 
countries (n=77)
p value† High-income countries 
(n=164)
p value‡
Male sex 58 (50%) 0·976 38 (49%) 0·247 94 (57%) 0·199
Age at death (months) 5·0 (2·3–11·0) 0·973 4·0 (2·0–10·0) 0·023 7·0 (3·6–16·8) 0·006
Younger than 6 months at death 68 (58%) 0·893 44 (57%) 0·014 66 (40%) 0·003
Prematurity§ 9 (8%) 0·083 12 (16%) 0·043 45 (27%) 0·000
Gestational age (weeks) 38·0 (38·0–39·0); n=22 0·144 38·0 (34·5–38·0); n=38 0·250 38·1 (32·1–40·0); n=80 0·688
Comorbidity§ 33 (28%) 0·008 36 (47%) 0·001 114 (70%) 0·000
Oxygen saturation on room air at 
hospital admission (%)
92·0% (85·8–97·3); n=94 0·022 87·0% (85·0–94·0); n=47 0·448 89·0% (76·5–91·0); n=37 0·001
Weight for age Z score of less than –2 64/111 (58%) 0·924 33/58 (57%) 0·370 49/99 (50%) 0·236
Contact with health-care provider 
before admission to hospital
28/65 (43%) 0·870 17/38 (45%) 0·123 41/68 (60%) 0·047
Time between onset of symptoms and 
admission (days)
5·0 (3·0–7·0); n=71 0·002 3·0 (2·0–4·0); n=45 0·387 3·0 (1·0–5·0); n=135 0·000
Length of stay in hospital (days) 3·0 (2·0–6·0) 0·000 7·0 (3·0–11·5) 0·000 15·0 (7·0–32·0); n=149 0·000
Availability of intensive care unit 28 (24%) 0·000 75 (97%) 0·038 164 (100%) 0·000
Intensive care unit admission 23/116 (20%) 0·000 27/56 (48%) 0·000 152 (93%) 0·000
Mechanical ventilation 23/114 (20%) 0·000 33/60 (55%) 0·000 138/155 (89%) 0·000
Urban living area 22/66 (33%) 0·000 39/40 (98%) 0·867 129/133 (97%) 0·000
At least one sibling present in household 30/39 (77%) 0·122 16/17 (94%) 0·003 62/109 (57%) 0·027
Time of death relative to RSV seasonality
Death during RSV season 61/79 (77%) 0·004 35/64 (55%) 0·000 122/134 (91%) 0·005
Death within 1 month before or after 
RSV season
7/79 (9%) 0·050 13/64 (20%) 0·001 7/134 (5%) 0·303
Data are n (%), median (IQR), or n/N (%). Statistical comparisons with Mann-Whitney U test or χ² test with p values of less than 0·0167 taken to be significant according to 
Bonferroni correction for multiple testing. RSV=respiratory syncytial virus. *Low-income or lower middle-income country versus upper middle-income country. 
†Upper middle-income country versus high-income country. ‡Low-income or lower middle-income country versus high-income country. §Considered absent when missing. 
Table: Clinical characteristics and risk factors in RSV-related child deaths
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is the first descriptive study of global RSV-related 
mortality using individual case records. We studied 
clinical characteristics of children who died with RSV in 
hospitals across the world. We supplemented data from 
previously published cases of RSV-related in-hospital 
death with unpublished data by contacting individual 
investigators, research groups, and networks. Complete 
clinical information was generally available for children 
from high-income countries, but clinical data from low-
income and middle-income countries were often 
incomplete. For the first time, we showed that a 
substantial proportion of in-hospital RSV-related deaths 
in young children occurred in those with severe 
comorbidities. In low-income and middle-income 
countries, most children who died with RSV infection 
were aged younger than 6 months.
This study describes, to our knowledge, the largest 
number of children with RSV-related mortality to date. 
We obtained good global representation, with coverage of 
all six continents. Clinical profiles of children who die 
with RSV are essentially diﬀerent in lower-income 
countries, where most childhood RSV-associated 
mortality occurs.1,5 In low-income or lower middle-income 
countries, we found that at least 28% of deaths occurred 
in children with severe comorbidities, such as congenital 
heart disease. Our data suggest that most RSV-related in-
hospital deaths in both low-income and middle-income 
countries occur in children aged younger than 6 months. 
Most children with comorbidities (eg, severe prematurity 
or congenital heart disease) in these countries might 
already have died during neonatal age. Additionally, a 
longer time interval between the onset of symptoms and 
admission to hospital in low-income countries than in 
middle-income and high-income countries and a lower 
proportion of children being admitted to intensive care 
units and receiving mechanical ventilation in low-income 
and middle-income countries than in high-income 
countries suggest that high RSV mortality in these 
countries might reflect limitations in health-care quality 
or access to care rather than specific susceptibility of 
the children. Young age at death of children with 
comorbidities in low-income and middle-income 
countries might have been related to low access to care as 
well. Paediatric intensive care was available to only 24% of 
children from low-income or lower middle-income 
countries and to most children from upper middle-
income countries, although only 48% of these children 
were actually admitted to the intensive care unit. 
The role of comorbidities in RSV-related childhood 
mortality has mostly been described in high-income 
countries.10,11,24 The diﬀerences in characteristics of 
children with or without comorbidities were in line with 
previously published data from high-income settings. 
Previous studies10,11,13,14,25,26 have also described a higher age 
of children with comorbidities at admission or death 
than of previously healthy children, whereas young age is 
a risk factor for severe RSV disease in otherwise healthy 
preterm children.27 For high-income countries, we 
substantiate that the age distribution of children who die 
with RSV infection is substantially diﬀerent between 
children with and without severe comorbidities.
Figure 3: Age distribution at the time of RSV-related death in children
Low-income or lower middle-income countries (A), upper middle-income countries (B), and high-income countries (C). 
RSV=respiratory syncytial virus.
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Several strategies to prevent RSV infection and 
RSV-related mortality are being developed.28 Age at 
death could influence the eﬀectiveness of perinatal 
immunisation strategies, including passive immun-
isation by maternal vaccination during pregnancy and 
administration of RSV-specific long-half-life monoclonal 
antibody at birth. Our age distribution data suggest that 
maternal vaccination will be more eﬀective for healthy 
term children than for children with comorbidities 
because antibody concentrations decrease after birth over 
time. Our data suggest that children with comorbidities 
will need additional preventive interventions, such as 
extended passive immunisation or infant vaccination to 
optimise prevention of RSV-related mortality.
A key strength of this study is that we obtained most 
previously published cases of RSV-related mortality in 
children and supplemented this data with data sourced 
through existing networks, leading to a sample size large 
enough to draw robust conclusions and do some sensitivity 
analyses. Second, we verified the quality of each case 
record through direct interaction with the local researchers. 
Finally, RSV GOLD is a case series with global represen-
tation. Limitations also deserve discussion. First, although 
RSV GOLD forms, to our knowledge, the largest case 
series of RSV-related childhood mortality in hospital, this 
case series still reflects only a small proportion of all 
RSV-related deaths worldwide, as most global acute lower 
respiratory tract infection deaths occur outside of hospital.29 
Data are scarce for RSV-related deaths in the community. 
Second, in RSV GOLD, only 117 (33%) of the children 
studied were from low-income or lower middle-income 
countries, which contrasts with the estimate that 99% of 
RSV-related mortality occurs in developing countries.5 
Third, RSV GOLD is a case series, which does not allow 
for calculation of eﬀect sizes of risk factors for 
RSV-associated mortality. A population-based study16 from 
Buenos Aires reported sepsis and pneumothorax as 
clinical risk factors for RSV-associated mortality, although 
sepsis was not pathogen specific. To calculate risk ratios 
for global RSV-related death with use of original case 
records, a large prospective population-based study would 
be needed, which would be challenging given the 
estimated RSV-attributable mortality rate of 0·86–0·94 per 
1000 livebirths.16 Fourth, our data are limited by several 
biases. Data are primarily from research sites with 
availability of diagnostic tests for RSV and RSV diagnostics 
changing over time, with more sensitive molecular 
diagnostics used after 2005 than before 2005 (selection 
bias). Diﬀerences in the proportion of available data 
between income regions could have caused additional 
selection bias. For example, white blood count and 
haemoglobin concentration were more often available in 
low-income regions, which probably reflects 
measurements in a clinical research setting. Some authors 
who published data for RSV-related deaths did not respond 
(response bias), and data for prematurity and comorbidities 
were often missing, particularly from low-income and 
middle-income countries (misclassification bias). 
Misclassification bias could have led to inaccurate 
interpretation of results. The estimated prevalence of 
comorbidities in children from low-income or lower 
middle-income countries is probably an underestimation 
caused by missing data for comorbidities, but could also 
be an overestimation caused by selection bias due to a 
research setting, for example. However, results from our 
sensitivity analysis supported the main results of our study. 
Finally, since a substantial proportion of sociodemographic 
data were missing, these data should be interpreted with 
caution. For example, the high proportion of RSV-related 
deaths outside of the RSV season in some countries could 
reflect inaccurate seasonality data, but could also result 
from year-round RSV activity, as most of these countries 
had subtropical climates.
RSV-related infection is an important cause of death in 
children aged younger than 5 years. Data for RSV-related 
deaths are scarce and, when available, these data are 
limited to in-hospital deaths in research settings. 
Additionally, data for some of the key variables, such as 
comorbidities and gestational age, are missing. RSV 
GOLD is being further expanded to collect data for RSV-
related deaths from any health facility or community-
based study worldwide. Investments to understand the 
cause of death in young children need to be sustained to 
inform vaccine policy, particularly in low-income and 
middle-income settings.
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